PrevaCept Infection Control, Inc. manufacturers the best-in-class product for catheter infection control, the PrevaCept Lock Solution. PrevaCept has been shown to dramatically reduce the risk of sepsis caused by catheters colonized by microbial pathogens. PrevaCept Lock Solution is a broad-spectrum catheter lock solution that rapidly kills Gram positive, Gram negative and fungal pathogens in biofilm.
Central line associated blood stream infections (CLABSI) are difficult to treat, costing
up to $50,000 per course of treatment and are responsible for significant attributable
mortality (12-25%). In the U.S. the aggregate cost of treatment for CLABSI is estimated
to exceed five billion dollars annually.
Patients with central venous catheters (CVCs), both in hospital and outpatient settings, often develop CLABSI caused by biofilm-pathogens. Those patients at greatest risk for CLABSI are found in intensive care units (ICU) as well as vulnerable patients with chronic conditions who are treated with CVCs. These include cancer patients undergoing infusion therapy, end-stage renal disease patients on hemodialysis and patients with catastrophic gastrointestinal disease receiving total parenteral nutrition (TPN).
Market estimates are based on the prevalence of patients with vascular access in the US and Europe by treatment category and duration of vascular access. Frequency of administration is based on the standard of catheter care using saline or heparin lock.
CEO and Board Member
Chief Medical Officer
Director of RA/QA
Fred is a Managing Partner of Charter Life Sciences (CLS), a life sciences focused venture capital fund.
John Neis is a Managing Director of Venture Investors LLC since and heads the firm's Healthcare practice
Michael Fulton is a Managing Director of Hopen Life Sciences LLC a healthcare focused venture capital firm located in Grand Rapids, MI.
Jean Kanerva is a Principal at Charter Life Sciences where she is involved in fund and portfolio management.